Celadon Pharmaceuticals Key Figures| Key Figures | | (at previous day's close) |
| Market Cap. | 1,184.93 | m |
| Shares In Issue | 8.03 | m |
| Prev. Close | 147.50 | |
| PE Ratio | - | |
| Dividend Yield | - | % |
| EPS - basic | -3.60 | p |
| Dividend PS | - | p |
| Dividend Cover | - | |
| Cash Flow PS | -2.17 | p |
| Return On Equity (ROE) | -3.40 | % |
| Operating Margin | - | % |
| PEG Factor | - | |
| EPS Growth Rate | - | % |
| Dividends PS Growth Rate | - | % |
| Dívida Líquida | -5.61 | m |
| Gross Gearing | 0.58 | % |
| Quick Assets | 5.66 | m |
| Net Working Capital | 5.64 | m |
| Intangibles / Fixed Assets | - | % |
| Turnover PS | - | p |
| Pre-Tax Profit PS | -2.38 | p |
| Retained Profit PS | -2.38 | p |
| Cash PS | 70.30 | p |
| Net Cash PS | 70.04 | p |
| Net Tangible Asset Value PS * | 70.09 | p |
| Net Asset Value PS | 70.09 | p |
| Spread | 15.00 (9.68%) | |
| * Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies. |
|
Celadon Pharmaceuticals Balance Sheet
 Share Price Performance
Share Price Chart (5 years)| Share Price Chart (5 years) |  |
|
Celadon Pharmaceuticals Historic Returns
|
Celadon Pharmaceuticals Key Management Ratios
|
Celadon Pharmaceuticals Investment Ratios| %1$s Investment Ratios | | (Market value analysis) at previous day's close |
| PQ Ratio | - | |
| PE Ratio | - | |
| Tobin's Q Ratio | 209.22 | |
| Tobin's Q Ratio (excl. intangibles) | 209.22 | |
| Dividend Yield | - | % |
| Market-to-Book Ratio | 210.45 | |
| Price-to-Pre-Tax Profit PS | -6,193.43 | |
| Price-to-Retained Profit PS | -6,193.43 | |
| Price-to-Cash Flow PS | -6,808.01 | |
| Price-to-Sales PS | - | |
| Price-to-Net Tangible Asset Value PS | 210.45 | |
| Price-to-Cash PS | 209.80 | |
| Net Working Capital PS | 70.24 | |
| Price Pct to Working Capital PS | 210.00 | % |
| Earnings Yield | - | % |
| Average PE | - | |
| Years in average | - | |
| PE to PE average | - | % |
|
Celadon Pharmaceuticals Financial Ratios| %1$s Financial Ratios | | (Leverage Ratios) |
| Debt Ratio | 0.21 | % |
| Debt-to-Equity Ratio | 0.00 | |
| Debt-to-Equity Ratio (excl. Intgbl) | 0.00 | |
| Debt-to-Equity Market Value | 0.00 | |
| Net Gearing | -99.14 | % |
| Net Gearing (excl. Intangibles) | -99.14 | % |
| Gross Gearing | 0.58 | % |
| Gross Gearing (excl. Intangibles) | 0.58 | % |
| Gearing Under 1 Year | 0.37 | % |
| Gearing Under 1 Year (excl. Intgbl) | 0.37 | % |
| Assets/Equity | 1.01 | |
| Cash/Equity | 100.31 | |
| (Liquidity Ratios) |
| Net Working Capital to Total Assets | 99.63 | % |
| Current Ratio | 270.45 | |
| Quick Ratio (Acid Test) | 270.45 | |
| Liquidity Ratio | 269.70 | |
| Cash & Equiv/Current Assets | 99.72 | % |
| (Solvency Ratios) |
| Enterprise Value | 1,179.29 | m |
| CFO/Sales | - | |
| CFO/Attributable Profit | - | |
| CFO/Assets | -0.03 | |
| CFO/Debt | -5.28 | |
| Total Debt/Equity Market Value | 0.00 | |
| Total Debt/Sales | - | |
| Total Debt/Pre-Tax Profit | -0.17 | |
| Total Debt | 0.03 | m |
| Total Debt/Net Current Assets | 0.01 | % |
| (Dodds - Graham Ratios) | | |
| 3 yr Compound Earnings Growth | - | % |
| 5 yr Compound Earnings Growth | - | % |
| 10 yr Compound Earnings Growth | - | % |
| Earn drops > 5% in 10yrs | - | |
| Beta coefficients | | Beta (60-Mnth) | Beta (36-Mnth) | | 0.0179 | 0.0553 |
|
Celadon Pharmaceuticals Operating Ratios| %1$s Operating Ratios | | (Profitability Ratios) |
| Return On Capital Employed (ROCE) | -3.39 | % |
| Return On Assets (ROA) | -3.38 | % |
| Net Profit Margin | - | % |
| Assets Turnover | - | |
| Return On Equity (ROE) | -3.40 | % |
| Return On Investment (ROI) | -3.39 | % |
| Dividend Payout Ratio | - | % |
| Plowback Ratio | 100.00 | % |
| Growth from Plowback Ratio | - | % |
| Net Income Of Revenues | - | % |
| (Asset Utilisation Multiples) |
| Shareholders Equity Turnover | - | |
| Fixed Assets Turnover | - | |
| Current Assets Turnover | - | |
| Net Working Capital Turnover | | |
| Inventory Turnover | - | |
| (Other Operating Ratios) |
| Total Assets-to-Sales | - | |
| Debtors-to-Sales | - | % |
| Debt Collection Period | - | Dias |
|
Celadon Pharmaceuticals Dividends
|
|
Celadon Pharmaceuticals Fundamentals |
| Profit and Loss Account | | | 31 Ago 2019 (GBP) | |
| turnover | - | - | m |
| pre tax profit | -0.19 | - | m |
| attributable profit | -0.19 | - | m |
| retained profit | -0.19 | - | m |
| eps - basic (p) | -3.60 | | |
| eps - diluted (p) | -3.60 | | |
| dividends per share | - | | |
| | | |
|
Celadon Pharmaceuticals Balance Sheet| Balance Sheet | | | 31 Ago 2019 (GBP) | |
 |   | |
|
| | 31 Ago 2019 (GBP) | |
| ASSETS | | | |
 fixed assets | - | -% | m |
 intangibles | - | -% | m |
| fixed investments | - | -% | m |
 current assets - other | - | -% | m |
| stocks | - | -% | m |
| debtors | 0.02 | 0.28% | m |
 cash & securities | 5.65 | 99.72% | m |
|
| TOTAL | 5.66 | 100% | m |
|
| LIABILITIES | | | |
 creditors - short | 0.02 | 0.37% | m |
 creditors - long | 0.01 | 0.21% | m |
| creditors - other | - | -% | m |
| subordinated loans | - | -% | m |
| insurance funds | - | -% | m |
|
| TOTAL | 0.03 | 0.58% | m |
|
| EQUITY | | | |
 ord cap, reserves | 5.63 | 99.42% | m |
| prefs, minorities | - | -% | m |
|
| TOTAL | 5.63 | 99.42% | m |
|
| OTHER | | | |
| NAV Basic | - | | |
| NAV Diluted | - | | |
|
Celadon Pharmaceuticals Cash Flow Statement| %1$s Cash Flow Statement | | 31 Ago 2019 (GBP) | |
| Operating CF | -0.17 | m |
| Pre-Financing CF | -0.17 | m |
| Retained CF | 5.65 | m |
| | |
|
Celadon Pharmaceuticals Brokers
|
| |
| |
| |
| |